Clinical Trial Update: TACE Combined With Sintilimab Plus Bevacizumab Biosimilar in Hepatocellular Carcinoma (BCLC-C Stage ): a Prospective Single-arm Phase II Clinical Study [Phase 2]

View source ↗

Summary

Phase II single-arm trial evaluating TACE combined with sintilimab and a bevacizumab biosimilar in hepatocellular carcinoma (BCLC-C).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Bevacizumab biosimilar (Bevacizumab)
• Sintilimab (sintilimab)
• TACE

Snippet

Sponsor: Sun Yat-sen University | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN